CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor

LA JOLLA, Calif., January 5, 2017 /PRNewswire/ — Privately-held CalciMedica, Inc., announced that it started Phase 1 safety studies in healthy volunteers of a novel calcium release-activated calcium (CRAC) channel inhibitor, CM4620, intended to treat acute pancreatitis. Acute pancreatitis, sudden painful inflammation of the pancreas, is typically a mild disorder, but can be very serious. …

CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor Read More »